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Background: There is paucity of detailed studies of adult T cell acute lymphoblastic leukemia (T-ALL) in developing countries 
reflecting the condition of these patients including clinical and biological features. Objective: This study was carried out to analyze 
the immunophenotypic characteristics of 40 Moroccan patients with T-ALL and its association with biological and clinical features. 
Patients and Methods: Between 2006 and 2009, 130 adult patients diagnosed with acute lymphoblastic leukemia (ALL) were im-
munophenotyped by 3-color flow cytometry using a panel of monoclonal antibodies. Cases presenting features of a T-lineage 
phenotype were subjected to detailed analysis including immunophenotypic, clinical and biological parameters. Results: Proportion 
of T-ALL among ALL Moroccan patients was 31.0%. Median age of patients was 28 years. Twenty-nine patients were females 
and 11 were males. 45.0% of patients (18/40) had features of immature T-ALL stages (pro-T and pre-T ALL), 30.0% (12/40) 
of CD1a+ cortical T-ALL stage and 25.0% (10/40) had a characteristic phenotype of medullary T-ALL. The frequencies of pro-
genitor cell markers CD10, CD34 and TdT expression were 14.0; 57.5% and 50.0% respectively. The aberrant expression of B li-
neage associated antigen CD79a were positive in 20.5% of the cases and the aberrant expression of myeloid antigens CD13 and/
or CD33 was found in 22 (55.0%) cases. No significant association was encountered between TdT, CD34 or myeloid antigens 
positivity and high risk features at presentation as age, sex, and white blood cells. However, myeloid antigens (CD13 and/or CD33) 
was significantly associated with T-cell maturation stages (p = 0.009). Conclusion: To the best of our knowledge, this is the first 
report from North Africa of immunophenotypic study on adult T-ALL. Our findings indicate that the proportion of T-ALL among 
ALL in Morocco is similar to that reported in others Mediterranean countries like France and Italy and that myeloid-associated 
antigens expression is frequently associated with immature immunophenotype.
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Acute lymphoblastic leukemia (ALL) represents 
a biologically and clinically heterogeneous group 
of diseases characterized by the accumulation of im-
mature lymphoid cells within the bone marrow (BM) 
and lymphoid tissues. ALL represents about 80% 
of acute leukemias in childhood, where it is the most 
frequent malignancy, and accounts for about 20% 
of adult acute leukemias [1].
Early classification systems for acute leukemias 
were based only on morphological and cytochemical 
investigations. Morphology still plays a central role, but 
current World Health Organization (WHO) classifi cation 
of tumors of hematopoietic and lymphoid tissues incor-
porates also immunophenotyping, cytogenetic and mo-
lecular characteristics that contribute towards defining 
bio logically and clinically relevant leukemia subsets [2].
Flow cytometric immunophenotyping of ALL 
is fundamental in the modern diagnosis and treatment 
of acute leukemia for several reasons. First, the utiliza-
tion of larger panels of monoclonal antibodies to B-cell, 
T-cell and myeloid as well as non-lineage-restricted 
antigens allows characterization of blast cells by line-
age assignment, evaluation of cell maturation, and 
assessment of phenotypic aberrations. Second, immu-
nophenotyping is also essential for recognizing several 
subtypes of acute myeloid leukemia (AML) (e.g., mini-
mally differentiated, myeloperoxidase-nega tive AML 
and acute megakaryoblastic leukemia) and mixed phe-
notype acute leukemia. Finally, immunophenotyping 
is important for monitoring the response to treatment, 
including detection of minimal residual disease and 
for identifying markers with prognostic implica tion [3].
Malignant lymphoid neoplasms involving the pre-
sence of neoplastic immature lymphoid cells of T-cell 
lineage in both the blood and the BM have been 
designated as precursor T cell acute lymphoblastic 
leukemia (T-ALL)/lymphoblastic lymphoma (T-LBL) 
in the recently published WHO classification for he-
matologic neoplasms. When there is extensive involve-
ment in both the BM and the blood, the preferred term 
is leukemia. However, if a mass lesion is present with 
minimal blood and BM involvement, the appropriate 
term is lymphoma [2].
The most important studies about T-ALL/LBL 
come from developed countries with regard to their 
distribution according to the classical intrathymic 
differentiation compartments, clinical features, de-
scription of prognostic factors as well as the outcome. 
The purpose of this study is to determine, by flow 
cytometry, the frequency and immunophenotypic 
features of Moroccan patients with T-ALL. The immu-
nophenotypic findings were correlated to biological 
and clinical features in comparison with B-lineage ALL.
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MATERIALS AND METHODS
Patients. From January 2006 to December 2009, 
immunophenotyping was successfully performed 
in 130 consecutive adults (≥18 years) newly diagnosed 
with ALL (other than L3 subtypes) at the Hematology 
and Oncology Hospital, Casablanca, Morocco. Cases 
presenting features of a T-lineage phenotype were 
subjected to detailed analysis including immuno-
phenotypic, clinical and biological parameters. ALL 
diagnosis was performed on May-Grunwald — Gi-
emsa smears. BM or peripheral blood (PB) samples 
were collected, prior to treatment, on ethylenediami-
netetraacetic acid (EDTA) tubes. All patients were 
con sented to the routine laboratory and hospital 
procedures including blood and BM studies. Patients 
were analyzed for age, gender, morphological FAB 
subtypes, white blood cells (WBC) count, platelets 
count and hemoglobin levels, lymphoadenopathy, 
splenomegaly, hepatomegaly and cytogenetic data.
Flow cytometry. All EDTA-anticoagulated PB/
BM samples were immediately transported to the Cy-
tometery Laboratory of the National Hygiene Institute 
of Morocco for immunophenotyping. All the samples 
were evaluated by flow cytometry, using CD45 expres-
sion vs side scatter to analyze the blast cell population 
as described earlier [4]. T-lymphoid antigens included 
CD1a, CD3, CD4, CD5, CD7 and CD8; B-lymphoid 
antigens included CD10, CD19, CD22, and cytoplas-
mic CD79a. Myeloid antigens were myeloperoxidase 
(MPO), CD13 and CD33. Precursor-cell antigens 
analyzed were CD34, HLA-DR, and TdT. Positive sta-
ining was defined as at least 20% of blast cells sho-
wing expression of the marker of interest. T-lineage 
ALL patients were diagnosed based on the positive 
expression of CD3 (cytoplasmic and/or surface) and 
were classified further into three maturational stages 
that were defined as immature T-ALL stage (pro-T and 
pre-T ALL): sCD3–, cCD3+, CD7+, CD1a–, CD5+ and/
or CD8+; cortical T-ALL stage: positive for CD1a (ir-
respective of other markers), and medullary T-ALL: 
positive for surface CD3 and negative for CD1a (ir-
respective of other markers).
Statistical analysis. The analysis was done using 
SPSS 17.0 version. The characteristics of the patients 
were compared by the exact χ2 or Fisher tests. All tests 
were 2-sided with a p value of less than 0.05 indicating 
a statistically significant difference.
RESULTS AND DISCUSSION
Immunophenotypic findings. Of the 130 ALL 
cases immunophenotyped, 40 (31.0%) cases were 
classified as having T-ALL and 84 (64.5%) cases were 
classified as having B-ALL disease. Mixed acute leuke-
mia comprised 6 (4.5%) cases  and were dropped from 
further evaluation. Table 1 summarizes the frequencies 
of antigens expression found in 40 patients diagnosed 
with T-ALL in comparison with B-ALL. The cyto-
plasmic CD3 and CD7 were the only surface T-cell 
antigens expressed by all cases (100.0%), followed 
by CD5 (82.0%), surface CD3 (62.5%), CD4 (34.0%) 
and CD8 (31.5%). Co-expression of CD4 and 
CD8 was observed in 21.0% of cases whereas lack 
of expression of them both was observed in 55.0% 
of cases. CD10 was found in 5 cases (14.0%) and 
absent in 31 (86.0%) of 36 cases tested for CD10. 
CD34 (57.5%), TdT (50%) and HLA-DR positivity 
(25.0%) were significantly much lower in T-ALL than 
those in B-ALL (77.5; 84.0 and 100.0%, respectively). 
The aberrant expression of B-lineage associated an-
tigen CD79a was positive in 20.5% of the cases and 
the aberrant expression of myeloid antigens CD13 and/
or CD33 was found in 22 cases (55.0%), more fre-
quently CD13 than CD33. Indeed, CD13 was observed 
in 17 (42.5%) patients, whereas CD33 was observed 
in 10 (25.0%) cases. Both CD13 and CD33 antigens 
were expressed in 5 (12.5%) cases. No difference 
was observed in myeloid antigen expression be-
tween T-ALL and B-ALL subgroups (55.0% vs 52.5%, 
p = 0.744). According to surface antigens expression 
by leukemic cells, 45.0% of patients (18/40) had 
features of immature T-ALL phenotype (pro-T and 
pre-T ALL), 30.0% (12/40) of cortical T-ALL subtype 
and 25.0% (10/40) of medullary T-ALL subtype. Early 
T cell precursor-ALL, a very poor prognosis subgroup 
defined by its associated distinctive immunopheno-
type (CD1a–, CD8–, CD5 weak with stem-cell/myeloid 
markers) [5, 6], was found in 6 (15.0%) cases.
Table 1. Number of patients and frequency (%) cells with individual mar-
ker expression in B-ALL and T-ALL
CD B-ALL (n = 84) T-ALL (n = 40) p
CD1a − 12 (31.5) −
CytCD3 0 (0.0) 40 (100.0) < 0.001
CD3 0 (0.0) 25 (62.5) < 0.001
CD4 − 13 (34.0) −
CD5 − 32 (82.0) −
CD7 3 (3.5) 40 (100.0) < 0.001
CD8 − 12 (31.5) −
CD10 51 (60.5) 5 (14.0) < 0.001
CD13 29 (36.5) 17 (42.5) 0.507
CD19 84 (100.0) 1 (2.5) < 0.001
CD22 84 (100.0) 2 (5.5) < 0.001
CD33 24 (29.0) 10 (25.0) 0.649
CD34 65 (77.5) 23 (57.5) 0.023
CD45 72 (91.0) 36 (97.0) 0.433
CD79a 78 (100.0) 7 (20.5) < 0.001
TdT 68 (84.0) 19 (50.0) < 0.001
HLA-DR 84 (100.0) 10 (25.0) < 0.001
CD4+/CD8+ − 8 (21.0) −
CD4–/CD8– − 21 (55.0) −
CD13+ and/or CD33+ 42 (52.5) 22 (55.0) 0.744
CD13+/ CD33+ 10 (12.5) 5 (12.5) 1.0
Relationship between immunophenotype and 
disease characteristics
Clinical characteristics by lineage. Baseline cha-
racteristics of T-ALL patients compared with B-ALL 
patients are summarized in Table 2. T-ALL and  B-ALL 
significantly differed in their presentation. T-cell 
disease was more commonly seen in males (72.5% 
vs 52.5%, p = 0.033). T-cell disease was more com-
mon in the 18 to 35 years age group (75.0% vs 56.0%, 
p = 0.041). There was an association between T-cell 
disease and a high WBC with 52.5% of T-ALL pa-
tients having a WBC more than 50 000/μl compared 
with 31.0% of B-cell patients (p = 0.021). There 
was no statistically significant difference between 
groups in terms of splenomegaly and hepatome-
66 Experimental Oncology 37, 64–69, 2015 (March)
galy frequencies whereas lymphadenopathy seems 
to be associated with the T-phenotype rather than 
with the B-phenotype (84.0% vs 57.0%, p = 0.014). 
Cytogenetic data are available for 96 cases including 
71 cases of B-ALL and 25 cases for T-ALL. Normal 
diploid caryotypes were more frequently in T-lineage 
ALL patients than in B-lineage ALL patients (55.0% 
vs 29.0%; p = 0.035). The immunophenotype of leu-
kemic blasts from patients with t(9;22) and with t(4;11) 
were restricted to B-ALL.
Table 2. Comparison of clinical and biological features of Moroccan adult 
patients with B-ALL and T-ALL
Variable
All patients, 
n (%)
B-ALL, 
n (%)
T-ALL, 
n (%) p
124 (100.0) 84 (67.5) 40 (32.5)
Age
Median 31 (18–66) 34 (18–66) 28 (18–66)
≤ 35 77 (62.0) 47 (56.0) 30 (75.0) 0.041
> 35 47 (38.0) 37 (44.0) 10 (25.0)
Sex
male 73 (59.0) 44 (52.5) 29 (72.5) 0.033
female 51 (41.0) 40 (47.5) 11 (27.5)
FAB
ALL L1 11 (9.0) 8 (9.5) 3 (7.5) 0.758
ALL L2 98 (79.0) 67 (79.5) 31 (77.5)
NS 15 (12.0) 9 (11.0) 6 (15.0)
Clinical features*
Lymphadenopathy (%) 69 (63.5) 48 (57.0) 21 (84.0) 0.014
Splenomegaly, 
≥ 2 cm (%)
43 (40.0) 32 (39.0) 11 (44.0) 0.657
Hepatomegaly, 
≥ 2 cm (%)
27 (27.0) 17 (22.5) 10 (40.0) 0.084
Laboratory data
Leukocyte count 27 325 (510–
513 050)
21 700 
(510–
450 000)
50 500 
(600–
513 050)
Median (range), /μl
< 50 000/μl 77 (62.0) 58 (69.0) 19 (47.5) 0.021
≥ 50 000/μl 47 (38.0) 26 (31.0) 21 (52.5)
Hemoglobin level* 7.3 
(3.0–15.4)
6.9 
(3.0–12.8)
9.2 
(4.7–15.4)Median (range), g/dl
< 10 g/dl 86 (81.0) 72 (89.0) 14 (56.0) 0.001
≥ 10 g/dl 20 (19.0) 9 (11.0) 11 (44.0)
Platelet count* 32 500 
(2000–
570 000)
30 000 
(2000–
570 000)
51 000 
(10 000–
236 000)
Median (range), /μl
< 100 000/μl 90 (84.0) 71 (86.5) 19 (76.0) 0.220
≥ 100 000/μl 17 (16.0) 11 (13.5) 6 (24.0)
Cytogenetic**
Normal 30 (35.5) 19 (29.0) 11 (55.0) 0.035
Abnormal 55 (65.0) 46 (71.0) 9 (45.0)
Ph 18 (21.0) 18 (27.5) 0 (0.0) 0.008
t(4.11) 4 (4.5) 4 (6.0) 0 (0.0) 0.569
Unsuccessful karyotype 11 (11.5) 6 (8.5) 5 (20.0)
*Complete data are available for 107 cases including 82 cases of B-ALL and 
25 cases for T-ALL.
**Cytogenetic data are available for 96 cases including 71 cases of B-ALL 
and 25 cases for T-ALL.
NS — not specified; FAB — French-American-British classification; Ph — Phi-
ladelphia chromosome.
Comparison of clinical characteristics in T-cell 
maturational stages. The main clinical characteristics 
of the 40 patients divided into three immune subtypes 
according to the pattern of antigens expression are 
summarized in Table 3. As the number of patients 
was relatively small and for the purpose of statistic 
comparison we arbitrarily defined two groups: imma-
ture group (pro-T and pre-T ALL stages) and mature 
group (cortical-T and medullary-T stages). As shown 
in Table 3, patients in the mature group had a signifi-
cantly high initial white cell count (more than 50 000/μl) 
than those in the immature group (59.0% vs 28.0%, 
p = 0.048). In contrast, no significant diffe rence was 
observed between the two groups in regard to the oth-
ers initial characteristics such age, sex, platelets, he-
moglobin levels, organ (lymph nodes, liver and spleen) 
enlargement and cytogenetic findings.
Table 3. Characteristics of the 40 consecutive patients with T-ALL (n, %)
Variable
Immature 
(Pro- and 
pre-T)
Cortical-T Medullary-T Mature p
18 (45.0) 12 (30.0) 10 (25.0) 22 (55.0)
Age
Median 28 (18–66) 23 (18–58) 27 (19–49) 28 (18–66)
≤ 35 11 (61.0) 10 (83.5) 9 (90.0) 19 (86.5) 0.140
> 35 7 (39.0) 2 (16.5) 1 (10.0) 3 (13.5)
Sex
male 12 (66.5) 9 (75.0) 8 (80.0) 17 (77.5) 0.455
female 6 (33.5) 3 (25.0) 2 (20.0) 5 (22.5)
FAB
ALL L1 2 (11.0) 0 (0.0) 1 (10.0) 1 (4.5) 0.332
ALL L2 12 (66.5) 11 (92.0) 8 (80.0) 19 (86.5)
NS 4 (22.0) 1 (8.5) 1 (10.0) 2 (9.0)
Clinical fea-
tures*
Lymphadenopa-
thy (%)
6 (75.0) 11 (91.5) 4 (80.0) 15 (88.0) 0.570
Splenomegaly, 
≥ 2 cm (%)
3 (30.0) 5 (62.5) 3 (43.0) 8 (53.5) 0.414
Hepatomegaly, 
≥ 2 cm (%)
4 (44.5) 4 (40.0) 2 (33.5) 6 (37.5) 1.000
Leukocyte count
Median (range), /μl 21 900 
(600–
513 050)
49 800 
(1060–
496 000)
125 450 
(8880–
253 000)
79 875 
(1060–
496 000)
< 50 000/μl 13 (72.0) 6 (50.0) 3 (30.0) 9 (41.0) 0.048
≥ 50 000/μl 5 (28.0) 6 (50.0) 7 (70.0) 13 (59.0)
Hemoglobin level*
Median (range), 
g/dl
7.2 
(4.7–14.20)
10.0 
(5.0–15.40)
10.15 
(7.10–12.50)
10.0 
(5.0–15.40)
< 10 g/dl 7 (78.0) 4 (40.0) 3 (50.0) 7 (44.0) 0.208
≥ 10 g/dl 2 (22.0) 6 (60.0) 3 (50.0) 9 (56.0)
Platelet count*
Median (range), /μl 70 000 
(16 000–
167 000)
50 000 
(10 000–
236 000)
50 000 
(13 000–
131 000)
50 000 
(10 000–
236 000)
< 100 000/μl 5 (62.5) 7 (70.0) 6 (85.5) 13 (76.5) 0.640
≥ 100 000/μl 3 (37.5) 3 (30.0) 1 (14.5) 4 (23.5)
Cytogenetic*
Normal 5 (55.5) 2 (20.0) 3 (50.0) 5 (31.5) 0.458
Abnormal 3 (33.5) 5 (50.0) 2 (33.5) 7 (44.0)
Echec 1 (11.0) 3 (30.0) 1 (16.5) 4 (25.0)
* Complete data are available for 25 cases.
NS — not specified; FAB — French-American-British classification.
p-value indicated that when comparing the immature group and the ma-
ture group. The immature group was consisted of pro-T and pre-T stage, 
and the mature group was consisted of cortical-T and medullary-T stage.
Clinical characteristics in relation to TdT, CD34 and 
myeloid antigens expression in T ALL. No significant 
association was encountered between CD34, TdT 
or myeloid antigens positivity and the presenting clinical 
and biological features studied (Table 4) apart a statisti-
cal significance association between myeloid antigens 
expression and T-cell maturation stages as 63.5% 
of the cases expressing myeloid associated markers 
were of the immature phenotype compared with 22% 
of the myeloid antigens negative cases (p = 0.009).
T-ALL/LBL is an aggressive neoplasm derived from 
T-cell progenitors. The disease can initially present 
as lymphoblastic lymphoma involving thymus, nodal, 
and extranodal sites, and/or as ALL involving prima-
rily PB and BM. This work constitutes the first study 
to be carried out in Morocco involving characteriza-
tion of the immunopheno typic profile of cases of adult 
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 T-ALL. Our results on the frequency of T-ALL (31%) 
subtype was close to the frequency reported by some 
authors for France (28.5%) [7] and Italy (26.0%) [8] but 
this frequency was higher to the values found in USA 
(20.0%) [9] and lower than the percentage reported for 
Egypt (50%) [10] and India (53.0%) [11]. The reason for 
the differences in the frequency of T-cell immunophe-
notype is unclear. According some publications, T-ALL 
is more commonly associated with low socioeconomic 
status [12].
When we analyzed the association between clini-
cal and laboratory findings with T-ALL and B-ALL im-
munophenotypic subtypes of ALL, we could confirm 
previously published data [13–15] indicating that T-ALL 
occurs more frequently in males younger than 35 years 
of age and is usually accompanied by a high WBC 
count and tumor mass. On the other hand, we con-
firmed that leukemia of the T-cell lineage is commonly 
associated with a normal karyotype [16].
Immunophenotyping is essential in the diagnostic 
workup of T-ALL/LBL. Lymphoblasts express cytoplas-
mic and/or surface CD3 and other T-lineage makers 
(CD1a, CD2, CD4, CD5, CD7 or CD8) as well as one 
or more markers of immaturity, including CD1a, CD10, 
CD34 and terminal deoxynucleotidyl transferase (TdT). 
The latter is a unique intranuclear DNA polymerase that 
catalyzes the template-independent addition of de-
oxynucleotides to the 3´-hydroxyl terminus of oligo-
nucleotide primers [17] causing insertion of N regions 
during immunoglobulin and T-cell receptor (TCR) gene 
rearrangements at the DJ and VDJ junction sites [18, 
19]. This mechanism of junctional diversity is essential 
to the development of an adult-type immunoglobulin 
and TCR repertoire [19]. The presence, frequency, 
and clinical significance of TdT in T-ALL have not been 
examined extensively. In this study, TdT was expressed 
in 50.0% of our patients with T-ALL. This expression 
was lower than that detected in recent studies con-
ducted by Zhou et al. [20] and Patel et al. [21] who 
detected TdT expression in about 90.0% of T-ALL 
cases. The reasons for the differences may be attrib-
uted to different sensitivities of the antibodies as well 
as different cut-off levels for the discrimination of posi-
tive and negative cases. Others methodological varia-
tions in detection of TdT expression like fluorochrome 
labe ling, varying gates in flow cytometric analysis and 
different TdT antibodies recognizing distinct TdT epi-
topes must also be taken in consideration when com-
paring studies on the implications of TdT expression. 
On th other hand, TdT negative cases should be carefully 
differentiated from mature T-cell neoplasms particularly 
in cases that are also negative for HLA-DR and CD34.
Table 4. Presenting clinical and biological features in relation to TdT, CD34 and myeloid antigens (CD13 and/or CD33) expression in the studied adult 
 T-ALL patients (n, %)
Variable TdT+ TdT− p CD34+ CD34− p MyAg+ MyAg− p19 (50.0) 19 (50.0) 23 (57.5) 17 (42.5) 22 (55.0) 18 (45.0)
Age
Median 28 (18–66) 27 (18–50) 31 (18–66) 25.5 (18–58) 30 (19–66) 24 (18–49)
≤ 35 14 (73.5) 16 (84.0) 0.693 17 (74.0) 13 (76.5) 1.000 15 (68.0) 15 (83.5) 0.464
> 35 5 (26.5) 3 (16.0) 6 (26.0) 4 (23.5) 7 (32.0) 3 (16.5)
Sex
male 13 (68.5) 14 (73.5) 0.721 16 (69.5) 13 (76.5) 0.730 14 (63.5) 15 (83.5) 0.286
female 6 (31.5) 5 (26.5) 7 (30.5) 4 (23.5) 8 (36.5) 3 (16.5)
FAB
ALL L1 0 (0.0) 3 (16.0) 0.104 1 (4.5) 2 (12.0) 0.595 3 (13.5) 0 (0.0) 0.265
ALL L2 17 (89.5) 12 (63.0) 19 (82.5) 12 (70.5) 16 (72.5) 15 (85.5)
NS 2 (10.5) 4 (21.0) 3 (13.0) 3 (17.5) 3 (13.5) 3 (16.5)
Clinical features*
Lymphadenopathy (%) 10 (100.0) 8 (72.5) 0.214 10 (77.0) 11 (91.5) 0.593 9 (75.0) 12 (92.5) 0.322
Splenomegaly, ≥ 2 cm (%) 7 (50.0) 4 (40.0) 0.697 6 (37.5) 5 (55.5) 0.434 6 (40.0) 5 (50.0) 0.697
Hepatomegaly, ≥ 2 cm (%) 4 (28.5) 6 (60.0) 0.211 5 (31.5) 5 (55.5) 0.397 3 (23.0) 7 (58.5) 0.111
Leukocyte count
Median (range), /μl 25 000 
(1060–
205 000)
106 000 
(6070–
513 050)
66 000 (600–
513 050)
41 000 (1060–
496 050)
21 900 (600–
513 050)
79 875 (1060–
496 000)
< 50 000/μl 12 (63.0) 9 (47.5) 0.328 11 (48.0) 11 (64.5) 0.289 14 (63.5) 8 (44.5) 0.225
≥ 50 000/μl 7 (37.0) 10 (52.5) 12 (52.0) 6 (35.5) 8 (36.5) 10 (55.5)
Hemoglobin level*
Median (range), g/dl 9.5 
(4.7–15.40)
8.85 
(7.10–14.20)
7.5 
(4.70–14.20)
10.9 
(8.00–15.40)
7.6 
(4.70–14.20)
10 
(5.0–15.40)
< 10 g/dl 8 (53.5) 4 (50.0) 1.000 12 (70.5) 2 (25.0) 0.032 10 (71.5) 4 (36.5) 0.116
≥ 10 g/dl 7 (46.5) 4 (50.0) 5 (29.5) 6 (75.0) 4 (28.5) 7 (63.5)
Platelet count*
Median (range), /μl 52 000 
(12 000–
236 000)
35 000 
(10 000–
131 000)
52 000 
(10 000–
167 000)
50 000 
(12 000–
236 000)
52 000 
(12 000–
167 000)
50 000 
(10 000–
236 000)
< 100 000/μl 10 (77.0) 7 (78.0) 1.000 13 (76.5) 5 (71.5) 1.000 10 (77.0) 8 (73.0) 1.000
≥ 100 000/μl 3 (23.0) 2 (22.0) 4 (23.5) 2 (28.5) 3 (23.0) 3 (27.0)
Cytogenetic*
Normal 7 (46.5) 3 (43.0) 0.896 7 (46.5) 3 (30.0) 0.659 5 (38.5) 5 (42.0) 0.923
Abnormal 5 (33.5) 3 (43.0) 5 (33.5) 5 (50.0) 5 (38.5) 5 (42.0)
Echec 3 (20.0) 1 (14.0) 3 (20.0) 2 (20.0) 3 (23.0) 2 (16.0)
T cell stage*
Immature 6 (31.5) 10 (52.5) 0.189 12 (52.0) 6 (35.5) 0.289 14 (63.5) 4 (22.0) 0.009
Mature 13 (68.5) 9 (47.5) 11 (48.0) 11 (64.5) 8 (36.5) 14 (78.0)
*Complete data are available for 25 cases.
NS — not specified; FAB — French-American-British classification.
68 Experimental Oncology 37, 64–69, 2015 (March)
CD7 was always detected in our T-ALL series. 
Although it is one of the most sensitive T-cell marker, 
CD7 lacks specificity, as cases of AML or natural killer 
cell leukemia can express CD7 too [22]. In the cur-
rent WHO classification system [2], CD3 expression 
is considered the only T-cell lineage-specific marker 
and is required for T-cell lineage assignment.
CD10 was detected in 14.0% of the T-ALL cases and 
CD34 was expressed in 57.5% of cases. The CD10 an-
tigen was originally known as common ALL antigen 
(cALLA). It was one of the first markers to identify acute 
leukemia in children. In the hematopoietic system, 
CD10 regulates stromal dependent B lymphopoiesis. 
The majority of B-lineage ALL cases expressed CD10. 
However, expression of CD10 has also been reported 
in other types of leukemia [23]. CD34 is a human 
stage-specific hematopoietic differentiation antigen, 
and expressed in early-undifferentiated hematopoietic 
stem cells, both in lymphoid and myeloid pathways. 
In leukemic cells, it remains expressed over several 
stages of lymphoid and myeloid maturation [24, 25]. 
In our study, the incidence of CD34 expression ap-
peared to be more frequent on B-ALL (77.5%) than 
T-ALL (57.5%). This is consistent with previous obser-
vations in both children [26–28] and adult series [22, 
29], suggesting a more immature hematopoietic cell 
involvement in B-ALL.
According to the stages of normal thymocyte deve-
lopment that they resemble, we stratified our 40 adult 
T-ALL cases into three maturational groups. The ma-
jority of cases (45.0%) arise from immature compart-
ment (pro-T and pre-T ALL). This finding is in agree-
ment with previous reports [30, 31]. Two recent studies 
have shown that a subset of T-ALL/LBL cases with 
an immunophenotype considered being of an early 
T-precursor origin (ETP) belongs to a very high risk 
group. The ETP immunophenotype is described as lack 
of CD1a and CD8, CD5-/weak, and expression of one 
or more myeloid or stem cell-related antigens [5, 6]. 
Both studies focused on pediatric patients and showed 
that ETP-positive cases represent 5–13% of T-ALL/LBL 
patients. In our study, we found that 6 cases (15.0%) 
met the criteria for early T-cell immunophenotype 
defined by the following immunoprofile: CD1a–, CD8–, 
and CD5+/weak with positivity for myeloid (CD13 and/
or CD33) or stem cell (CD34) antigens.
Malignant blasts often have an abnormal pheno-
type that allows distinction from normal immature 
cells. One of these abnormalities is the occurrence 
of aberrant phenotypes (or anomalous expression) 
which is defined by the co-expression of markers usu-
ally not present on cells of that particular lineage [32]. 
The frequency of aberrant expression of the B-cell 
antigen receptor complex associated protein CD79a 
in our T-ALL cases was 20.5% wish was higher than 
5.0% recently reported by Patel et al. [21]. The finding 
of CD3/CD79a coexpression in ALL raises the question 
of whether these CD79a positive cases are genuinely 
of T-cell lineage. Pilozzi et al. [33] performed gene 
rearrangement studies of the immunoglobulin heavy 
chain and TCR gamma genes in a series of CD3+ ALL 
with or without CD79a expression detected by im-
munohistochemistry. All of the cases studied showed 
TCR gamma gene rearrangement, and none showed 
solely immunoglobulin heavy chain gene rearrange-
ment, strongly suggesting that CD3+ cases of ALL are 
of T-cell lineage, regardless of CD79a expression.
The incidence of aberrant myeloid antigen expres-
sion in our study is 55.0%, an incidence much higher 
than reported previously for adult patients [21, 29, 
31] but more close to 51.0% reported by Marks 
et al. [34]. Disparities in flow cytometric technolo-
gy immunophenotyping could explain this different 
 finding. The frequency of myeloid coexpression was 
comparable in B and in T-ALL (52.5% vs 55.0%, 
p = 0.744). This was different from earlier reports that 
My antigen was significantly associated with T cell ALL 
cases [35]. The role of myeloid associated antigens 
in the prediction of clinical outcome is still controver-
sial. While the few early adult ALL studies had shown 
an inferior outcome for My+ ALL patients [36–38] ot-
hers have found similar outcomes [31, 35].
In conclusion, our findings indicate, first: that 
the overall immunoprofile of our T-ALL is gene rally 
similar to that described in small case series re-
ports [39–41], second: the proportion of T-ALL among 
ALL in Morocco is similar to that reported in others 
Mediterranean countries like France and Italy. Third, 
the expression of myeloid-associated antigens is asso-
ciated with immature immunophenotype of blast cells.
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